\
&
Contact us
This was 3 years ago
LocationClub University Foundation - Cattier room
THIS EVENT HAS BEEN CANCELLED
The NCP Flanders team presents the variety of opportunities of funding that is available in the Horizon Europe and Digital Europe Programmes with a specific focus on the opportunities for and concerns of private companies.
We shortly highlight relevant parts of the funding programmes and include, where feasible, a testimonial of a company that already has experience in participating in Horizon Europe or in a recent similar action under Horizon 2020.
Sufficient time for questions will be foreseen after each presentation.
Target audience: companies located in Flanders, interested in applying to Horizon Europe/Digital Europe
Registration - at latest on 7th of June: free but compulsory through this link
How to get to the venue:
By car: use the parking "2 Poorten”, a five minute walk to Club University Foundation. Main entrance - Waterloolaan 2a, 1000 Brussel - Alternative entrance - Avenue de la Toison d’Or (in front of Apple).
Language: English
Programme
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.